The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute to tumor cell growth, HER2. Despite this common trait, the development of ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

New Food and Drug Administration regulations went into effect on Sept ... to receive annual mammograms — X-ray imaging of ...

FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer ...

Consumers should be aware that some chocolate labeled as "dairy-free" actually contains milk, the U.S. Food and Drug ...

The most common breast cancer is HER2-negative, so called because it has low amounts of one of the proteins that contribute ...

AWESOME. GREAT INFORMATION. THANK YOU SO MUCH, The Food and Drug Administration now requires all mammogram reports to include a breast density assessment. This is because the risk of breast cancer is ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

The US Food and Drug Administration (FDA) has approved a 420 mg dosage strength of Hercessi (trastuzumab-strf), a biosimilar to Herceptin (trastuzumab). Hercessi, a HER2/neu receptor antagonist, is ...

Jazz Pharma's diversified drug portfolio drives revenue growth. Zanidatamab shows promise with potential FDA approval in late ...